Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease

NCT02760407 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1648

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: Olokizumab 64mg q4w
DRUG: Olokizumab 64mg q2w
DRUG: Adalimumab 40mg q2w
DRUG: Placebo q2w

Sponsor

R-Pharm International, LLC

Collaborators

[object Object]
[object Object]